{
    "hands_on_practices": [
        {
            "introduction": "Before we can compare treatments using observational data, we must first map out the complex web of factors that might influence both patient outcomes and treatment decisions. Directed Acyclic Graphs (DAGs) serve as an essential blueprint for this task, providing a rigorous framework to identify confounding variables. This exercise  will develop your ability to use DAGs to distinguish valid adjustment strategies from those that could introduce bias, a critical skill for designing sound comparative effectiveness studies.",
            "id": "4364917",
            "problem": "A health system is conducting Comparative Effectiveness Research (CER) to estimate the total causal effect of a new antihypertensive treatment on major cardiovascular events using observational data. Investigators represent their assumptions with a Directed Acyclic Graph (DAG). Let $T$ denote treatment assignment, $Y$ the outcome, $L$ measured baseline cardiovascular risk, $U$ an unmeasured biological risk factor, $M$ an intermediate post-treatment clinical response (for example, systolic blood pressure level after initiation), and $C$ a measure of care intensity (for example, frequency of follow-up encounters). The DAG is specified by the following arrows: $L \\to T$, $L \\to Y$, $T \\to M$, $M \\to Y$, $U \\to Y$, $U \\to C$, and $T \\to C$. All arrows are assumed correct, and there are no additional arrows. The goal is to identify a valid covariate adjustment set that yields an unbiased estimate of the total causal effect of $T$ on $Y$ in this setting.\n\nWhich option correctly identifies a minimal valid back-door adjustment set and correctly explains how conditioning on colliders or mediators would bias the effect estimate?\n\nA. Adjust for $\\{L\\}$ only. Conditioning on $C$ would introduce bias by opening the path $T \\to C \\leftarrow U \\to Y$, and conditioning on $M$ would block part of the causal effect from $T$ to $Y$, biasing the total effect estimate.\n\nB. Adjust for $\\{L, C\\}$. Conditioning on $C$ is necessary to block confounding through $U$ because $C$ lies between $U$ and $Y$, and conditioning on $M$ is optional since $M$ lies on the causal pathway.\n\nC. Adjust for $\\{L, M\\}$. Conditioning on $M$ is required to avoid overestimation because $M$ is downstream of $T$, and conditioning on $C$ is harmless since more adjustment cannot introduce bias.\n\nD. Adjust for $\\{L, C, M\\}$. More extensive adjustment is always safer; colliders do not create bias when conditioned upon, and mediators should be conditioned upon to isolate the direct effect even when the target estimand is the total effect.",
            "solution": "To identify a valid adjustment set for estimating the total causal effect of treatment $T$ on outcome $Y$, we must use the back-door criterion. This involves identifying all non-causal paths (back-door paths) between $T$ and $Y$ and finding a set of covariates to condition on that blocks all such paths, without creating new bias. We must not block any causal paths from $T$ to $Y$.\n\nLet's analyze the paths between $T$ and $Y$ based on the provided Directed Acyclic Graph (DAG):\n\n1.  **Path 1: $T \\to M \\to Y$**\n    This is a directed (causal) path from the treatment to the outcome. The variable $M$ is a mediator of the effect of $T$ on $Y$. To estimate the *total* causal effect, we must leave this path open. Conditioning on the mediator $M$ would block this path and would allow us to estimate only the direct effect of $T$ on $Y$, not the total effect. Therefore, we must **not** adjust for $M$.\n\n2.  **Path 2: $T \\leftarrow L \\to Y$**\n    This is a back-door path. $L$ is a common cause of both treatment $T$ and outcome $Y$. This path induces a non-causal association between $T$ and $Y$ (confounding), which will bias our estimate. To block this path and remove the confounding, we **must** condition on (adjust for) $L$.\n\n3.  **Path 3: $T \\to C \\leftarrow U \\to Y$**\n    This is another non-causal path. However, the variable $C$ is a **collider** on this path because two arrows point into it ($T \\to C$ and $U \\to C$). A path that contains a collider is naturally blocked. Conditioning on a collider (or a descendant of a collider) *unblocks* the path, creating a spurious association between $T$ and $Y$ through the unmeasured variable $U$. This is known as collider-stratification bias. Therefore, we must **not** adjust for $C$.\n\n**Conclusion:**\nTo obtain an unbiased estimate of the total causal effect, we must adjust for $L$ but not for $M$ or $C$. The minimal valid adjustment set is therefore $\\{L\\}$.\n\n**Evaluation of Options:**\n\n*   **A. Adjust for $\\{L\\}$ only. Conditioning on $C$ would introduce bias by opening the path $T \\to C \\leftarrow U \\to Y$, and conditioning on $M$ would block part of the causal effect from $T$ to $Y$, biasing the total effect estimate.** This statement is perfectly correct based on our analysis.\n*   **B.** Adjusting for $\\{L, C\\}$ is incorrect because conditioning on the collider $C$ introduces bias.\n*   **C.** Adjusting for $\\{L, M\\}$ is incorrect because conditioning on the mediator $M$ would lead to an estimate of the direct effect, not the total effect.\n*   **D.** Adjusting for $\\{L, C, M\\}$ is incorrect for both of the reasons above. The claim that more adjustment is always safer is false; conditioning on colliders or mediators can introduce bias.\n\nTherefore, the only correct option is A.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "After using a DAG to identify confounders, the next step is to apply a statistical method that adjusts for their influence to isolate the causal effect of the treatment. Inverse Probability Weighting (IPW) is a powerful technique that accomplishes this by reweighting individuals in the dataset to create a pseudo-population where confounders are balanced across treatment groups, much like in a randomized controlled trial. In this practice problem , you will move from theory to application by calculating the Average Treatment Effect (ATE) with an IPW estimator, gaining a concrete understanding of how this method corrects for imbalances in observational data.",
            "id": "4364875",
            "problem": "An observational comparative effectiveness study evaluates a new antihypertensive medication versus usual care. For each individual $i \\in \\{1,\\dots,n\\}$, let $T_i \\in \\{0,1\\}$ denote treatment status ($T_i=1$ if the new medication was received; $T_i=0$ otherwise), let $Y_i$ denote the $6$-month change in systolic blood pressure (in millimeters of mercury, $\\mathrm{mm\\,Hg}$; negative values indicate reductions), and let $\\hat{e}(X_i)$ denote the estimated propensity score, defined as the estimated probability of receiving treatment given measured covariates $X_i$. The study aims to estimate the causal effect of treatment on the outcome using inverse probability weighting (IPW), a method grounded in the potential outcomes framework and the law of iterated expectations, under the conditions of consistency, conditional exchangeability given covariates, and positivity.\n\nStarting from the fundamental definitions of potential outcomes $Y_i(1)$ and $Y_i(0)$, the Average Treatment Effect (ATE) defined as $\\mathbb{E}\\!\\left[Y(1)-Y(0)\\right]$, the propensity score $e(X)=\\mathbb{P}(T=1\\mid X)$, and the Horvitz–Thompson style reweighting logic, derive the IPW estimator of the ATE that uses weights based on $\\hat{e}(X_i)$ and then compute its value for the sample below. Finally, interpret the target estimand in words in the context of this study.\n\nUse the following data for $n=10$ individuals:\n- Individual $1$: $T_1=1$, $Y_1=-12$, $\\hat{e}(X_1)=0.70$.\n- Individual $2$: $T_2=1$, $Y_2=-8$, $\\hat{e}(X_2)=0.55$.\n- Individual $3$: $T_3=1$, $Y_3=-5$, $\\hat{e}(X_3)=0.40$.\n- Individual $4$: $T_4=1$, $Y_4=-10$, $\\hat{e}(X_4)=0.80$.\n- Individual $5$: $T_5=0$, $Y_5=-4$, $\\hat{e}(X_5)=0.35$.\n- Individual $6$: $T_6=0$, $Y_6=-2$, $\\hat{e}(X_6)=0.60$.\n- Individual $7$: $T_7=0$, $Y_7=-1$, $\\hat{e}(X_7)=0.25$.\n- Individual $8$: $T_8=1$, $Y_8=-7$, $\\hat{e}(X_8)=0.65$.\n- Individual $9$: $T_9=0$, $Y_9=-3$, $\\hat{e}(X_9)=0.50$.\n- Individual $10$: $T_{10}=0$, $Y_{10}=-6$, $\\hat{e}(X_{10})=0.20$.\n\nCompute the derived IPW estimator using these values. Round your final numerical answer to four significant figures. Express the final effect in $\\mathrm{mm\\,Hg}$.",
            "solution": "The problem is subjected to validation before proceeding to a solution.\n\n### Step 1: Extract Givens\n- **Study Context**: An observational comparative effectiveness study comparing a new antihypertensive medication ($T_i=1$) versus usual care ($T_i=0$).\n- **Sample Size**: $n=10$ individuals.\n- **Variables for individual $i$**:\n  - $T_i \\in \\{0, 1\\}$: Treatment status.\n  - $Y_i$: Observed outcome, which is the $6$-month change in systolic blood pressure in $\\mathrm{mm\\,Hg}$.\n  - $\\hat{e}(X_i)$: Estimated propensity score, representing the estimated probability of treatment conditional on covariates $X_i$, $\\hat{\\mathbb{P}}(T_i=1 \\mid X_i)$.\n- **Causal Framework and Assumptions**:\n  - Potential outcomes: $Y_i(1)$ (outcome under treatment) and $Y_i(0)$ (outcome under control).\n  - Target Estimand: Average Treatment Effect (ATE), $\\tau = \\mathbb{E}[Y(1) - Y(0)]$.\n  - Method: Inverse Probability Weighting (IPW) using Horvitz–Thompson style reweighting.\n  - Assumptions: Consistency ($Y_i = T_i Y_i(1) + (1-T_i)Y_i(0)$), conditional exchangeability ($Y(t) \\perp T \\mid X$ for $t \\in \\{0,1\\}$), and positivity ($0 < e(X) < 1$).\n- **Tasks**:\n  1. Derive the IPW estimator of the ATE.\n  2. Compute its value for the provided sample data.\n  3. Interpret the ATE in the context of the study.\n- **Data ($n=10$)**:\n  - $i=1$: $T_1=1$, $Y_1=-12$, $\\hat{e}(X_1)=0.70$\n  - $i=2$: $T_2=1$, $Y_2=-8$, $\\hat{e}(X_2)=0.55$\n  - $i=3$: $T_3=1$, $Y_3=-5$, $\\hat{e}(X_3)=0.40$\n  - $i=4$: $T_4=1$, $Y_4=-10$, $\\hat{e}(X_4)=0.80$\n  - $i=5$: $T_5=0$, $Y_5=-4$, $\\hat{e}(X_5)=0.35$\n  - $i=6$: $T_6=0$, $Y_6=-2$, $\\hat{e}(X_6)=0.60$\n  - $i=7$: $T_7=0$, $Y_7=-1$, $\\hat{e}(X_7)=0.25$\n  - $i=8$: $T_8=1$, $Y_8=-7$, $\\hat{e}(X_8)=0.65$\n  - $i=9$: $T_9=0$, $Y_9=-3$, $\\hat{e}(X_9)=0.50$\n  - $i=10$: $T_{10}=0$, $Y_{10}=-6$, $\\hat{e}(X_{10})=0.20$\n- **Calculation Requirement**: Round the final numerical answer to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientific Grounding**: The problem is well-grounded in the field of causal inference within health systems science and biostatistics. The concepts of potential outcomes, ATE, propensity scores, and IPW are standard and fundamental to this domain. The scenario is scientifically realistic.\n- **Well-Posedness**: The problem is well-posed. It clearly defines the estimand, provides all necessary data and assumptions, and asks for a specific derivation and calculation. The propensity scores are all strictly between $0$ and $1$, satisfying the positivity assumption for this sample.\n- **Objectivity**: The problem is stated using precise, objective, and formal language, free of any subjective or opinion-based content.\n\n### Step 3: Verdict and Action\nThe problem is deemed valid as it is scientifically grounded, well-posed, objective, and complete. I will proceed with the derivation and solution.\n\n### Derivation of the IPW Estimator for the ATE\n\nThe Average Treatment Effect (ATE) is defined as the expected difference between the potential outcomes under treatment and control:\n$$ \\tau = \\mathbb{E}[Y(1) - Y(0)] $$\nBy the linearity of expectation, this can be separated into two components:\n$$ \\tau = \\mathbb{E}[Y(1)] - \\mathbb{E}[Y(0)] = \\mu_1 - \\mu_0 $$\nWe will derive an estimator for each component, $\\mu_1$ and $\\mu_0$, using inverse probability weighting.\n\nFirst, consider $\\mu_1 = \\mathbb{E}[Y(1)]$. We can use the law of iterated expectations to write this as $\\mu_1 = \\mathbb{E}_X[\\mathbb{E}[Y(1) \\mid X]]$. The key insight of IPW is to construct a quantity whose expectation is $\\mu_1$. Consider the random variable $\\frac{TY}{e(X)}$, where $T$ is the treatment indicator, $Y$ is the observed outcome, and $e(X) = \\mathbb{P}(T=1 \\mid X)$ is the true propensity score. Its expectation is:\n$$ \\mathbb{E}\\left[\\frac{TY}{e(X)}\\right] = \\mathbb{E}_X\\left[\\mathbb{E}\\left[\\frac{TY}{e(X)} \\mid X\\right]\\right] $$\nConditioning on $X$, $e(X)$ is a constant, so:\n$$ \\mathbb{E}\\left[\\frac{TY}{e(X)} \\mid X\\right] = \\frac{1}{e(X)} \\mathbb{E}[TY \\mid X] $$\nThe term $\\mathbb{E}[TY \\mid X]$ expands to $\\mathbb{P}(T=1 \\mid X) \\mathbb{E}[Y \\mid T=1, X] + \\mathbb{P}(T=0 \\mid X) \\mathbb{E}[Y \\mid T=0, X] \\times 0$. By definition, $\\mathbb{P}(T=1 \\mid X) = e(X)$, so this simplifies to $e(X) \\mathbb{E}[Y \\mid T=1, X]$. Substituting this back gives:\n$$ \\mathbb{E}\\left[\\frac{TY}{e(X)} \\mid X\\right] = \\frac{1}{e(X)} [e(X) \\mathbb{E}[Y \\mid T=1, X]] = \\mathbb{E}[Y \\mid T=1, X] $$\nNow, we apply the causal assumptions. By the consistency assumption, for individuals who received treatment ($T=1$), their observed outcome is their potential outcome under treatment: $Y=Y(1)$. Thus, $\\mathbb{E}[Y \\mid T=1, X] = \\mathbb{E}[Y(1) \\mid T=1, X]$.\nBy the conditional exchangeability assumption ($Y(1) \\perp T \\mid X$), we have $\\mathbb{E}[Y(1) \\mid T=1, X] = \\mathbb{E}[Y(1) \\mid X]$.\nCombining these steps, we have shown:\n$$ \\mathbb{E}\\left[\\frac{TY}{e(X)}\\right] = \\mathbb{E}_X[\\mathbb{E}[Y(1) \\mid X]] = \\mathbb{E}[Y(1)] = \\mu_1 $$\nAn analogous derivation holds for $\\mu_0 = \\mathbb{E}[Y(0)]$. We consider the quantity $\\frac{(1-T)Y}{1-e(X)}$:\n$$ \\mathbb{E}\\left[\\frac{(1-T)Y}{1-e(X)}\\right] = \\mathbb{E}_X\\left[\\frac{1}{1-e(X)} \\mathbb{E}[(1-T)Y \\mid X]\\right] $$\nThe inner expectation is $\\mathbb{P}(T=0 \\mid X) \\mathbb{E}[Y \\mid T=0, X] = (1-e(X))\\mathbb{E}[Y \\mid T=0, X]$. This leads to:\n$$ \\mathbb{E}\\left[\\frac{(1-T)Y}{1-e(X)}\\right] = \\mathbb{E}_X[\\mathbb{E}[Y \\mid T=0, X]] $$\nBy consistency ($Y=Y(0)$ if $T=0$) and conditional exchangeability ($Y(0) \\perp T \\mid X$), this becomes $\\mathbb{E}_X[\\mathbb{E}[Y(0) \\mid X]] = \\mathbb{E}[Y(0)] = \\mu_0$.\nCombining the results for $\\mu_1$ and $\\mu_0$:\n$$ \\tau = \\mu_1 - \\mu_0 = \\mathbb{E}\\left[\\frac{TY}{e(X)}\\right] - \\mathbb{E}\\left[\\frac{(1-T)Y}{1-e(X)}\\right] = \\mathbb{E}\\left[\\frac{TY}{e(X)} - \\frac{(1-T)Y}{1-e(X)}\\right] $$\nBased on the method of moments, we can estimate this expectation by its sample average. This yields the Horvitz-Thompson style IPW estimator for the ATE, using the estimated propensity scores $\\hat{e}(X_i)$:\n$$ \\hat{\\tau}_{IPW} = \\frac{1}{n} \\sum_{i=1}^{n} \\left(\\frac{T_i Y_i}{\\hat{e}(X_i)} - \\frac{(1-T_i)Y_i}{1-\\hat{e}(X_i)}\\right) $$\nThis expression can be separated into contributions from the treated ($T_i=1$) and control ($T_i=0$) groups:\n$$ \\hat{\\tau}_{IPW} = \\frac{1}{n} \\sum_{i: T_i=1} \\frac{Y_i}{\\hat{e}(X_i)} - \\frac{1}{n} \\sum_{i: T_i=0} \\frac{Y_i}{1-\\hat{e}(X_i)} $$\nNote that $\\hat{\\tau}_{IPW} = \\hat{\\mu}_1 - \\hat{\\mu}_0$, where $\\hat{\\mu}_1 = \\frac{1}{n}\\sum_{i} \\frac{T_i Y_i}{\\hat{e}(X_i)}$ and $\\hat{\\mu}_0 = \\frac{1}{n}\\sum_{i} \\frac{(1-T_i)Y_i}{1-\\hat{e}(X_i)}$.\n\n### Computation of the Estimator\n\nWe now compute the value of $\\hat{\\tau}_{IPW}$ for the given sample of $n=10$.\n\nFirst, we calculate the sum of weighted outcomes for the treated individuals ($T_i=1$):\n- $i=1$: $\\frac{Y_1}{\\hat{e}(X_1)} = \\frac{-12}{0.70} \\approx -17.142857$\n- $i=2$: $\\frac{Y_2}{\\hat{e}(X_2)} = \\frac{-8}{0.55} \\approx -14.545455$\n- $i=3$: $\\frac{Y_3}{\\hat{e}(X_3)} = \\frac{-5}{0.40} = -12.5$\n- $i=4$: $\\frac{Y_4}{\\hat{e}(X_4)} = \\frac{-10}{0.80} = -12.5$\n- $i=8$: $\\frac{Y_8}{\\hat{e}(X_8)} = \\frac{-7}{0.65} \\approx -10.769231$\nThe sum for the treated group is:\n$$ \\sum_{i: T_i=1} \\frac{Y_i}{\\hat{e}(X_i)} \\approx -17.142857 - 14.545455 - 12.5 - 12.5 - 10.769231 = -67.457543 $$\nSo, the estimate for the mean potential outcome under treatment is $\\hat{\\mu}_1 = \\frac{-67.457543}{10} = -6.7457543$.\n\nNext, we calculate the sum of weighted outcomes for the control individuals ($T_i=0$):\n- $i=5$: $\\frac{Y_5}{1-\\hat{e}(X_5)} = \\frac{-4}{1-0.35} = \\frac{-4}{0.65} \\approx -6.153846$\n- $i=6$: $\\frac{Y_6}{1-\\hat{e}(X_6)} = \\frac{-2}{1-0.60} = \\frac{-2}{0.40} = -5.0$\n- $i=7$: $\\frac{Y_7}{1-\\hat{e}(X_7)} = \\frac{-1}{1-0.25} = \\frac{-1}{0.75} \\approx -1.333333$\n- $i=9$: $\\frac{Y_9}{1-\\hat{e}(X_9)} = \\frac{-3}{1-0.50} = \\frac{-3}{0.50} = -6.0$\n- $i=10$: $\\frac{Y_{10}}{1-\\hat{e}(X_{10})} = \\frac{-6}{1-0.20} = \\frac{-6}{0.80} = -7.5$\nThe sum for the control group is:\n$$ \\sum_{i: T_i=0} \\frac{Y_i}{1-\\hat{e}(X_i)} \\approx -6.153846 - 5.0 - 1.333333 - 6.0 - 7.5 = -25.987179 $$\nSo, the estimate for the mean potential outcome under control is $\\hat{\\mu}_0 = \\frac{-25.987179}{10} = -2.5987179$.\n\nFinally, the ATE estimate is the difference between these two estimated means:\n$$ \\hat{\\tau}_{IPW} = \\hat{\\mu}_1 - \\hat{\\mu}_0 \\approx -6.7457543 - (-2.5987179) = -4.1470364 $$\nRounding to four significant figures, the result is $-4.147$.\n\n### Interpretation of the Target Estimand\n\nThe target estimand, the Average Treatment Effect (ATE), $\\mathbb{E}[Y(1) - Y(0)]$, represents the average causal effect of the new medication compared to usual care on the $6$-month change in systolic blood pressure, across the entire population from which the sample was drawn. Specifically, it is the difference between the average systolic blood pressure change we would observe if every individual in the population took the new medication for $6$ months, and the average change we would observe if every individual in that same population instead received usual care for $6$ months. A negative value, as estimated here, suggests that the new medication causes a greater average reduction in systolic blood pressure than usual care. The estimated effect of $-4.147\\,\\mathrm{mm\\,Hg}$ indicates that, on average, the new medication is associated with an additional reduction of approximately $4.15\\,\\mathrm{mm\\,Hg}$ in systolic blood pressure over $6$ months compared to usual care.",
            "answer": "$$\n\\boxed{-4.147}\n$$"
        },
        {
            "introduction": "No matter how carefully we adjust for measured confounders, observational research always carries the risk that unmeasured factors could bias the results. Therefore, a crucial final step in comparative effectiveness research is to question the robustness of our findings. The E-value is a modern sensitivity analysis tool that quantifies the strength of unmeasured confounding required to entirely explain away an observed association. This exercise  will teach you to calculate and interpret the E-value, equipping you with a vital skill for critically assessing the evidence from observational studies.",
            "id": "4364910",
            "problem": "A nonrandomized comparative effectiveness research (CER) study compares a new anticoagulant to a standard agent for preventing clotting events in patients with atrial fibrillation. After adjusting for measured covariates, the estimated risk ratio (RR) for major bleeding with the new anticoagulant versus the standard agent is $RR=1.65$. To assess robustness to unmeasured confounding, you decide to quantify the minimum strength of association that an unmeasured confounder would need to have with both treatment assignment and the outcome on the risk ratio scale, conditional on measured covariates, in order to fully explain away the observed association (that is, to reduce the true causal risk ratio to $1$).\n\nStarting from the core definitions used in health systems science and comparative effectiveness research—namely, the definition of the risk ratio $RR$ as the ratio of risks between the exposed and unexposed groups, the concept of confounding as a common cause of treatment and outcome, and the well-tested bound linking the magnitude of unmeasured confounding to bias on the risk ratio scale—derive an expression for this minimum required strength under the simplifying assumption that the unmeasured confounder is binary and its associations with the treatment and outcome are equal on the risk ratio scale. Then, use your derived expression to compute the corresponding evidence value, also known as the E-value, for the observed $RR=1.65$.\n\nFinally, briefly interpret what the computed quantity implies about the degree of unmeasured confounding that would be necessary to explain away the observed association, assuming the measured covariates have been adequately adjusted.\n\nRound your final numerical answer to four significant figures and express it as a unitless decimal. Do not include any confidence intervals or uncertainty quantification in your answer.",
            "solution": "The problem as stated is scientifically grounded, well-posed, and objective. It presents a standard task in epidemiological methods and comparative effectiveness research: conducting a sensitivity analysis for unmeasured confounding using the E-value framework. The provided data are sufficient and consistent for deriving the requested expression and performing the calculation. The problem is therefore valid.\n\nWe begin by formalizing the problem. Let $E$ denote the exposure, where $E=1$ for the new anticoagulant and $E=0$ for the standard agent. Let $D$ denote the binary outcome, where $D=1$ for a major bleeding event and $D=0$ for no event. The observed risk ratio is given as $RR_{\\text{obs}} = 1.65$. This is the ratio of the risk of the outcome in the exposed group to the risk in the unexposed group:\n$$RR_{\\text{obs}} = \\frac{P(D=1|E=1)}{P(D=1|E=0)}$$\nThe goal is to assess the potential impact of an unmeasured confounder, $U$, on this observed association. We are asked to find the minimum strength of association that $U$ must have with both $E$ and $D$ to fully explain away the observed effect. \"Explaining away\" means that the true causal risk ratio, $RR_{\\text{true}}$, is equal to $1$, and the observed association is entirely an artifact of confounding.\n\nThe relationship between the observed risk ratio, the true risk ratio, and confounding bias can be expressed as $RR_{\\text{obs}} = RR_{\\text{true}} \\times B$, where $B$ is the bias factor. If the effect is to be entirely explained by confounding, then $RR_{\\text{true}} = 1$, which implies $B = RR_{\\text{obs}}$.\n\nThe problem asks us to use the \"well-tested bound linking the magnitude of unmeasured confounding to bias on the risk ratio scale\". For a single, unmeasured, binary confounder $U$, an established bound on the bias factor $B$ is given by the parameters that characterize the confounder's associations with the exposure and the outcome. Let $RR_{EU}$ be the risk ratio for the association between the confounder and the exposure, and let $RR_{UD}$ be the risk ratio for the association between the confounder and the outcome, conditional on the measured covariates. The maximum bias factor, $B_{\\text{max}}$, that can be produced is bounded. A key result from the literature (Ding & VanderWeele, 2016) gives the maximum possible bias factor as:\n$$B \\le \\frac{RR_{EU} \\cdot RR_{UD}}{RR_{EU} + RR_{UD} - 1}$$\nThis bound holds under the worst-case scenario for the confounder's prevalence and assumes that both $RR_{EU} > 1$ and $RR_{UD} > 1$.\n\nThe problem introduces the simplifying assumption that the confounder's associations with treatment and outcome are equal on the risk ratio scale. Let us denote this common strength of association by $\\gamma$.\n$$ \\gamma = RR_{EU} = RR_{UD} $$\nSubstituting $\\gamma$ into the inequality for the bias factor, the maximum possible bias becomes:\n$$ B \\le \\frac{\\gamma \\cdot \\gamma}{\\gamma + \\gamma - 1} = \\frac{\\gamma^2}{2\\gamma - 1} $$\nTo find the minimum value of $\\gamma$ that could explain away the observed risk ratio $RR_{\\text{obs}}$, we set the observed risk ratio equal to this maximum possible bias:\n$$ RR_{\\text{obs}} = \\frac{\\gamma^2}{2\\gamma - 1} $$\nWe now solve this equation for $\\gamma$.\n$$ RR_{\\text{obs}} (2\\gamma - 1) = \\gamma^2 $$\n$$ 2\\gamma \\cdot RR_{\\text{obs}} - RR_{\\text{obs}} = \\gamma^2 $$\nRearranging the terms gives a quadratic equation in $\\gamma$:\n$$ \\gamma^2 - (2 \\cdot RR_{\\text{obs}})\\gamma + RR_{\\text{obs}} = 0 $$\nWe solve this equation for $\\gamma$ using the quadratic formula, $\\gamma = \\frac{-b \\pm \\sqrt{b^2 - 4ac}}{2a}$, with $a=1$, $b = -2 \\cdot RR_{\\text{obs}}$, and $c = RR_{\\text{obs}}$.\n$$ \\gamma = \\frac{2 \\cdot RR_{\\text{obs}} \\pm \\sqrt{(-2 \\cdot RR_{\\text{obs}})^2 - 4(1)(RR_{\\text{obs}})}}{2(1)} $$\n$$ \\gamma = \\frac{2 \\cdot RR_{\\text{obs}} \\pm \\sqrt{4 \\cdot RR_{\\text{obs}}^2 - 4 \\cdot RR_{\\text{obs}}}}{2} $$\n$$ \\gamma = \\frac{2 \\cdot RR_{\\text{obs}} \\pm 2\\sqrt{RR_{\\text{obs}}^2 - RR_{\\text{obs}}}}{2} $$\n$$ \\gamma = RR_{\\text{obs}} \\pm \\sqrt{RR_{\\text{obs}}(RR_{\\text{obs}} - 1)} $$\nThis yields two potential solutions for $\\gamma$. However, $\\gamma$ represents the strength of a confounding association, which must be greater than $1$ to create a positive bias (for an observed $RR_{\\text{obs}} > 1$). Let's examine the smaller root, $\\gamma_{-} = RR_{\\text{obs}} - \\sqrt{RR_{\\text{obs}}(RR_{\\text{obs}} - 1)}$. For any $RR_{\\text{obs}} > 1$, we have $RR_{\\text{obs}} - 1 < \\sqrt{(RR_{\\text{obs}} - 1)^2} < \\sqrt{RR_{\\text{obs}}(RR_{\\text{obs}} - 1)}$. Thus, $RR_{\\text{obs}} - \\sqrt{RR_{\\text{obs}}(RR_{\\text{obs}} - 1)} < 1$. Since a confounding risk ratio must be greater than $1$ to induce the observed positive association, the smaller root is not the relevant solution. The minimum required strength of association must be the larger root.\n\nTherefore, the expression for the minimum required strength, which is the definition of the E-value, is:\n$$ E\\text{-value} = \\gamma = RR_{\\text{obs}} + \\sqrt{RR_{\\text{obs}}(RR_{\\text{obs}} - 1)} $$\n\nNext, we compute the E-value for the observed risk ratio of $RR_{\\text{obs}} = 1.65$.\n$$ E\\text{-value} = 1.65 + \\sqrt{1.65(1.65 - 1)} $$\n$$ E\\text{-value} = 1.65 + \\sqrt{1.65(0.65)} $$\n$$ E\\text{-value} = 1.65 + \\sqrt{1.0725} $$\n$$ E\\text{-value} \\approx 1.65 + 1.03561576 $$\n$$ E\\text{-value} \\approx 2.68561576 $$\nRounding to four significant figures, we get $2.686$.\n\nFinally, we interpret this result. An E-value of $2.686$ implies that for an unmeasured confounder to fully account for the observed risk ratio of $1.65$, it would need to be associated with both the exposure (receiving the new anticoagulant) and the outcome (major bleeding) with a risk ratio of at least $2.686$ each, conditional on the measured covariates that were already adjusted for in the analysis. For example, if an unmeasured genetic factor were the confounder, it would need to increase the odds of a patient receiving the new drug by a factor of $2.686$ and also independently increase the risk of major bleeding by a factor of $2.686$. The plausibility of the observed association being entirely due to confounding can be judged by considering whether such a strong confounder that was not measured is likely to exist. A larger E-value suggests greater robustness of the finding to unmeasured confounding. In this case, a researcher would have to assess if a confounder with associations of magnitude $2.686$ is plausible in the context of atrial fibrillation treatment.",
            "answer": "$$\n\\boxed{2.686}\n$$"
        }
    ]
}